Table 3.
Cox proportional hazards model of prognosticators for PFS
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P | HR(95%CI) | P | HR(95%CI) | |
| Age (> 60 y vs ≤ 60 y) | 0.279 | 0.75 (0.44–1.26) | – | – |
| Sex (male vs female) | 0.321 | 0.99 (0.97–1.01) | – | – |
| ECOG (PS1 vs PS0) | 0.061 | 1.69 (0.98–2.93) | 0.168 | 1.48(0.85–2.58) |
| Surgery (Yes vs No) | 0.293 | 0.73 (0.41–1.31) | – | – |
| TACE (Yes vs No) | 0.509 | 1.95 (0.27–14.16) | – | – |
| Ablation (Yes vs No) | 0.273 | 1.36 (0.78–2.36) | – | – |
| Second line | ||||
| (TKI-ICI vs TKI) | < 0.001 | 0.34 (0.2–0.56) | < 0.001 | 0.35(0.21–0.59) |
| Number (> 3 vs ≤ 3) | 0.173 | 0.68 (0.4–1.18) | – | – |
| Size (> 5 cm vs ≤ 5 cm) | 0.508 | 0.84 (0.49–1.42) | – | – |
| PVTT (Yes vs No) | 0.891 | 0.97 (0.58–1.6) | – | – |
| Metastases (Yes vs No) | 0.321 | 0.78 (0.47–1.28) | – | – |
| Child–Pugh (B7 vs A) | 0.808 | 0.93 (0.53–1.64) | – | – |
| BCLC (C vs B) | 0.476 | 0.81 (0.46–1.44) | – | – |
| AFP (> 400 ng/mL vs ≤ 400 ng/mL) | 0.342 | 1.28 (0.77–2.13) | – | – |
PFS progression-free survival, HR(95%CI) hazard ratio(95% confidence interval), ECOG PS Eastern Cooperative Oncology Group performance status, TACE trans-arterial chemoembolization, TKI tyrosine kinase inhibitor, ICI immune checkpoint inhibitor, PVTT portal vein tumor thrombosis, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein